Krystal Biotech, Inc. Selling, General and Administrative Expense
Krystal Biotech, Inc. (KRYS) reported Selling, General and Administrative Expense of $39.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-03
- Krystal Biotech, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $39.85M, a 13.64% increase year-over-year.
- Krystal Biotech, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $41.01M, a 25.63% increase year-over-year.
- Krystal Biotech, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $41.45M, a 32.48% increase year-over-year.
- Krystal Biotech, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $37.58M, a 31.06% increase year-over-year.
- Krystal Biotech, Inc. selling, general and administrative expense for fiscal 2025 was $146.74M, a 29.14% increase from fiscal 2024.
- Krystal Biotech, Inc. selling, general and administrative expense for fiscal 2024 was $113.63M, a 15.60% increase from fiscal 2023.
- Krystal Biotech, Inc. selling, general and administrative expense for fiscal 2023 was $98.29M, a 26.44% increase from fiscal 2022.
- Krystal Biotech, Inc. selling, general and administrative expense for fiscal 2022 was $77.73M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $39.85M 10-Q · filed 2026-08-03 | $80.86M 10-Q · filed 2026-08-03 | $122.31M derived: sum of 3 quarters · filed 2026-08-03 | $159.89M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $41.01M 10-Q · filed 2026-05-04 | $82.46M derived: sum of 2 quarters · filed 2026-05-04 | $120.04M derived: sum of 3 quarters · filed 2026-05-04 | $155.11M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $41.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $79.03M derived: sum of 2 quarters · filed 2026-02-17 | $114.09M derived: sum of 3 quarters · filed 2026-08-03 | $146.74M 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | $37.58M 10-Q · filed 2025-11-03 | $72.65M derived: sum of 2 quarters · filed 2026-08-03 | $105.29M 10-Q · filed 2025-11-03 | $136.58M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $35.07M 10-Q · filed 2026-08-03 | $35.16M 10-Q · filed 2025-08-04 | $67.71M 10-Q · filed 2026-08-03 | $67.88M 10-Q · filed 2025-08-04 | $99.00M derived: sum of 3 quarters · filed 2026-08-03 | $127.67M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $32.65M 10-Q · filed 2026-05-04 | $32.72M 10-Q · filed 2025-05-06 | $63.93M derived: sum of 2 quarters · filed 2026-05-04 | $92.61M derived: sum of 3 quarters · filed 2026-05-04 | $120.23M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $31.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $59.96M derived: sum of 2 quarters · filed 2026-02-17 | $87.59M derived: sum of 3 quarters · filed 2026-02-17 | $113.63M 10-K · filed 2026-02-17 | $113.69M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $28.67M 10-Q · filed 2025-11-03 | $28.71M 10-Q · filed 2024-11-04 | $56.30M derived: sum of 2 quarters · filed 2025-11-03 | $82.34M 10-Q · filed 2025-11-03 | $82.40M 10-Q · filed 2024-11-04 | $107.01M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2024-06-30 | $27.63M 10-Q · filed 2025-08-04 | $53.69M 10-Q · filed 2025-08-04 | $78.34M derived: sum of 3 quarters · filed 2026-02-17 | $102.03M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2024-03-31 | $26.06M 10-Q · filed 2025-05-06 | $50.71M derived: sum of 2 quarters · filed 2026-02-17 | $74.41M derived: sum of 3 quarters · filed 2026-02-17 | $100.31M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2023-12-31 | $24.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $48.35M derived: sum of 2 quarters · filed 2026-02-17 | $74.25M derived: sum of 3 quarters · filed 2026-02-17 | $98.29M 10-K · filed 2026-02-17 | $98.40M 10-K · filed 2025-02-19 | |||
| 2023-09-30 | $23.70M 10-Q · filed 2024-11-04 | $49.60M derived: sum of 2 quarters · filed 2024-11-04 | $73.64M 10-Q · filed 2024-11-04 | $97.67M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $25.90M 10-Q · filed 2024-08-05 | $49.94M 10-Q · filed 2024-08-05 | $73.97M derived: sum of 3 quarters · filed 2025-02-19 | $93.90M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $24.04M 10-Q · filed 2024-05-06 | $48.06M derived: sum of 2 quarters · filed 2025-02-19 | $68.00M derived: sum of 3 quarters · filed 2025-02-19 | |||||
| 2022-12-31 | $24.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $43.97M derived: sum of 2 quarters · filed 2025-02-19 | $77.73M 10-K · filed 2025-02-19 | |||||
| 2022-09-30 | $19.93M 10-Q · filed 2023-11-06 | $53.70M 10-Q · filed 2023-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |